Measure intended to alleviate shortages of EpiPen
Last week, the U.S. Food and Drug Administration took measures to mitigate shortages of EpiPen auto-injector by extending the expiration dates of specific products by four months beyond the labeled date.
The changes, based on stability data provided by marketer Mylan and reviewed by the FDA, are intended to combat certain distribution issues within the United States. Regional supply disruptions and manufacturer issues are main contributors to the limited availability of EpiPen at the current time.
The FDA continues to work closely with Mylan on EpiPen production and supply, and also has been in contact with the other manufacturers of epinephrine auto-injectors, including Adrenaclick and Auvi-Q, regarding their supply as the school year begins since this is historically accompanied by increased product demand.